Breaking news：Shenghe Bioscience Breaks Through Hong Kong Stock Exchange, Three Core Products Lead Innovative Immune Battle
Shenghe Bioscience Holdings Limited, located in Huzhou, Zhejiang, was established in 2018, focusing on the research and development of biologics for cancer and autoimmune diseases. Recently, it has passed the hearing at the Hong Kong Stock Exchange and is planning to list on the main board of Hong Kong. With its three core products - IAH0968, IAP0971, IAE0972 developed independently, Shenghe Bioscience has demonstrated leading research and development capabilities in the global field of cancer treatment. IAH0968 is a monoclonal antibody that enhances antibody-dependent cell-mediated cytotoxicity (ADCC), targeting bile duct and colorectal cancer. IAP0971 and IAE0972, as antibody cytokines, have completed Phase I clinical trials for advanced solid tumors. Despite no sales revenue, Shenghe Bioscience, with its strong research and development capabilities and innovative products, has shown its ambition and potential in the field of biopharmaceuticals.
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
Market News
